Mission Biocapital

Venture Capital Exempt reporting adviser

Legal name: Mission Biocapital Management Company LLC

Cambridge, MA Website LinkedIn

AUM

$409.3M
Private fund assets

Private funds

3
Venture Capital 3

Private fund assets

$409.3M
Gross asset value

Employees

—

Last Form D raise

Nov 2025
Most recent fund filing

From SEC Form ADV filing (filed Mar 26, 2026). View on SEC

People(5)

Owners and executive officers named on the firm's SEC Form ADV.

D
Douglas Crawford
Managing General Partner, and Class A Member Mission Biocapital Management Company LLC
Source: SEC Form ADV
J
Johannes Fruehauf
General Partner and Class A Member, Mission Biocapital Management Company LLC
Source: SEC Form ADV
P
Peter Parker
Managing General Partner, CEO and Class A Member Mission Biocapital Management Company LLC
Source: SEC Form ADV
S
Steven Tregay
Managing General Partner, and Class A Member Mission Biocapital Management Company LLC
Source: SEC Form ADV
U
Ulrik Nielsen
General Partner
Source: SEC Form ADV

Funds(3)

Private funds reported on Form ADV, with amounts raised from the funds' SEC Form D filings.

FundTypeGross assetsRaised (Form D)InvestorsLast Form DRecency
Mission Biocapital VI LPVenture Capital$153.8M$143.8M11Nov 2025Warm
Mission Biocapital V LPVenture Capital$243.7M$191.9M—Apr 2021Cold
Mission Biocapital Platinum Program Holdings, LLCVenture Capital$11.8M———

Board seats(1)

Companies whose SEC Form D filings name one of this firm's people as a director, matched by name and office ZIP code.

Torque Therapeutics
BiotechnologyCambridge, MADirector: Ulrik Nielsen
$84.3M raised
Since Aug 2017
SEC Form D

Regulatory identifiers

CRD number
319585
SEC file number
802-125904

Sources